Pelthos Therapeutics Inc.
PTHS
$26.90
$0.602.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 658.63% | 342.17% | 466.92% | 478.56% | 223.35% |
| Gross Profit | 2,395.50% | 1,081.62% | 748.38% | -478.56% | -223.35% |
| SG&A Expenses | 843.26% | 564.20% | 296.49% | 24.53% | 30.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 855.47% | 550.16% | 208.09% | 0.78% | -5.21% |
| Operating Income | -484.70% | -328.33% | -131.15% | -0.78% | 5.21% |
| Income Before Tax | -701.24% | -537.42% | -138.83% | 7.73% | 18.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -600.88% | -444.56% | -134.21% | 7.73% | 18.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -600.88% | -444.56% | -134.21% | 7.73% | 18.00% |
| EBIT | -484.70% | -328.33% | -131.15% | -0.78% | 5.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -66.57% | -41.78% | 45.85% | 65.85% | 74.96% |
| Normalized Basic EPS | -84.76% | -57.18% | 45.37% | 65.85% | 74.96% |
| EPS Diluted | -66.57% | -41.78% | 45.85% | 65.85% | 74.96% |
| Normalized Diluted EPS | -84.76% | -57.18% | 45.37% | 65.85% | 74.96% |
| Average Basic Shares Outstanding | 328.46% | 235.04% | 169.28% | 81.02% | 173.16% |
| Average Diluted Shares Outstanding | 328.46% | 235.04% | 169.28% | 81.02% | 173.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |